180 related articles for article (PubMed ID: 29303950)
1. CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes-Tasimelteon as an Example.
Preskorn SH
J Psychiatr Pract; 2017 Nov; 23(6):425-430. PubMed ID: 29303950
[TBL] [Abstract][Full Text] [Related]
2. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
Bonacci JM; Venci JV; Gandhi MA
J Pharm Pract; 2015 Oct; 28(5):473-8. PubMed ID: 25092604
[TBL] [Abstract][Full Text] [Related]
3. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
Hardeland R
Curr Opin Investig Drugs; 2009 Jul; 10(7):691-701. PubMed ID: 19579175
[TBL] [Abstract][Full Text] [Related]
4. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
Neubauer DN
Drugs Today (Barc); 2015 Jan; 51(1):29-35. PubMed ID: 25685859
[TBL] [Abstract][Full Text] [Related]
5. Tasimelteon: a selective and unique receptor binding profile.
Lavedan C; Forsberg M; Gentile AJ
Neuropharmacology; 2015 Apr; 91():142-7. PubMed ID: 25534555
[TBL] [Abstract][Full Text] [Related]
6. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
Nishimon S; Nishimon M; Nishino S
Expert Opin Pharmacother; 2019 Jun; 20(9):1065-1073. PubMed ID: 30990759
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
Leger D; Quera-Salva MA; Vecchierini MF; Ogrizek P; Perry CA; Dressman MA
Expert Opin Drug Saf; 2015; 14(11):1673-85. PubMed ID: 26393492
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
Stahl SM
CNS Spectr; 2014 Dec; 19(6):475-8. PubMed ID: 25422900
[TBL] [Abstract][Full Text] [Related]
9. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
[TBL] [Abstract][Full Text] [Related]
10. Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder.
Med Lett Drugs Ther; 2014 Apr; 56(1441):34-5. PubMed ID: 24759294
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.
Torres R; Kramer WG; Baroldi P
J Clin Pharmacol; 2015 May; 55(5):525-33. PubMed ID: 25450415
[TBL] [Abstract][Full Text] [Related]
12. Tasimelteon: first global approval.
Dhillon S; Clarke M
Drugs; 2014 Mar; 74(4):505-11. PubMed ID: 24610704
[TBL] [Abstract][Full Text] [Related]
13. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
Johnsa JD; Neville MW
Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
[TBL] [Abstract][Full Text] [Related]
14. Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.
Ogilvie BW; Torres R; Dressman MA; Kramer WG; Baroldi P
J Clin Pharmacol; 2015 Sep; 55(9):1004-11. PubMed ID: 25851638
[TBL] [Abstract][Full Text] [Related]
15. CNS drug development: lessons learned part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approach.
Preskorn SH
J Psychiatr Pract; 2015 Jan; 21(1):60-6. PubMed ID: 25603452
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
[TBL] [Abstract][Full Text] [Related]
17. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.
Keating GM
CNS Drugs; 2016 May; 30(5):461-8. PubMed ID: 27003694
[TBL] [Abstract][Full Text] [Related]
18. CNS Drug Development, Lessons Learned, Part 5: How Preclinical and Human Safety Studies Inform the Approval and Subsequent Use of a New Drug-Suvorexant as an Example.
Preskorn SH
J Psychiatr Pract; 2018 Mar; 24(2):104-110. PubMed ID: 29509180
[TBL] [Abstract][Full Text] [Related]
19. Tasimelteon approved for circadian disorder in blind adults.
Traynor K
Am J Health Syst Pharm; 2014 Mar; 71(5):350. PubMed ID: 24534583
[No Abstract] [Full Text] [Related]
20. CNS drug development: part III: future directions.
Preskorn SH
J Psychiatr Pract; 2011 Jan; 17(1):49-52. PubMed ID: 21266894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
